Skip to content
etf.net

ARKG

GradeDChicago Board Options Exchange

ARK Genomic Revolution ETF

Themes · ARK · Inception 2014-10-31 · SEC filings

$50.88−2.00 (−3.77%)

As of Sep 23, 2026, 3:10 PM EDT

Intraday session: down, 69 prints from 52.87 to 50.88. Range 50.72 to 52.82. Use the arrow keys to read each point.$52.00$53.0010 AM12 PM2 PM4 PM
Expense ratio
0.75%
Fund size
$1.6B
1Y return
+89.8%
Yield · Last 12 months
0.00%
Volume · 30D
3.6M sh
NAV per share
$52.87
52W range
low $24.60high $53.40

The ETF.net ARKG Grade

D

33/ 100

Rank 16 of 17 in Biotech & Genomics⁠

Confidence High

Six-pillar profile for ARKG. Scores out of 100: Cost 6, Risk 12, Mission 46, Tradability 79, Holdings 31, Durability 73. Strongest: Tradability (79). Weakest: Cost (6). Leans toward Tradability and Durability.
F< 25
D≥ 25
C≥ 40
B≥ 55
A≥ 70

Score 33 of 100 sits in the D band. Bands: A ≥ 70, B ≥ 55, C ≥ 40, D ≥ 25, F < 25; the scale skips E.

  • Cost

    What you pay to own it — the expense ratio plus trading frictions, ranked within its category.
    FScore 6
    Category rank16/17 · bottom quartile

  • Mission

    How faithfully it does the job it claims — tracking its mandate or index with minimal slippage.
    CScore 46
    Category rank8/9 · bottom quartile

  • Risk

    How violently it can move — volatility, drawdown depth, and downside capture versus its category.
    FScore 12
    Category rank17/17 · bottom quartile

  • Tradability

    How cheaply and easily you can get in and out — liquidity, spread, and premium/discount stability.
    AScore 79
    Category rank4/17 · top 24%

  • Holdings

    What it actually owns — the quality, breadth, and concentration of the underlying portfolio.
    DScore 31
    Category rank16/17 · bottom quartile

  • Durability

    Whether it will still be here — the fund’s assets, age, flows, and issuer staying power.
    AScore 73
    Category rank5/17 · top 29%

Graded as of Sep 22, 2026

Our read on ARKG

ETF.net Research

DMost genomics exposure comes prepackaged in an index. ARKG is the active version: ARK's team hand-picks a global slate of companies tied to the genomics revolution, and has since 2014.

Stated mandate

The Fund seeks long-term growth of capital through active investment, primarily in domestic and foreign equity securities of companies relevant to the genomics revolution theme.

Why people hold it

  1. 01Active by design. ARK's managers choose the names instead of tracking a genomics index, so the portfolio can move as the science does.
  2. 02Global mandate. The prospectus puts both domestic and foreign equities in bounds, so the hunt for genomics names isn't fenced in at the US border.
  3. 03Live since 2014 and now a multibillion-dollar fund that trades actively, which makes getting in and out one of the easier parts of owning it.

Worth knowing

  1. 01The stock picking costs you: 0.75% a year, above the category median, while index rivals like IBB (0.44%) and XBI (0.35%) charge less for broad biotech.
  2. 02It sits at the more volatile end of its peer group. Concentrated bets on young science companies swing hard in both directions.
  3. 03Long-term growth of capital is the stated job. Income isn't part of the mandate, so there's no dividend cushioning the ride.

ARKG Holdings

As of Sep 20, 2026, 5:45 AM
Asset class
Stocks
Holdings
—
Top-10 weight
60%
Largest holding
TXG9.5%

Sectors

  • Health Care96.8%
  • Technology3.2%

Geography

  • United States90.94%
  • Switzerland5.74%
  • United Kingdom3.32%
The fund’s holdings, weight-ordered — page 1 of 3.
#TickerCompanyWeight %SharesMarket valueIn ETFs
001TXG10X GENOMICS INC-CLASS A9.46%2,710,594$209M136
002TEMTEMPUS AI INC-CL A9.23%2,533,783$204M100
003TWSTTWIST BIOSCIENCE CORP9.00%1,275,490$198M123
004CRSPCRISPR THERAPEUTICS AG5.72%2,200,818$126M83
005PSNLPERSONALIS INC5.13%6,966,209$113M58
006GHGUARDANT HEALTH INC4.99%600,811$110M171
007ABSIABSCI CORP4.59%10,912,545$101M64
008ILMNILLUMINA INC4.24%381,606$94M305
009NTRANATERA INC4.23%254,698$93M223
010CDNACAREDX INC3.82%1,551,983$84M105
011LLYELI LILLY & CO3.52%67,324$78M569
012CMPSCOMPASS PATHWAYS PLC3.22%4,734,894$71M16
013SDGRSCHRODINGER INC3.18%2,315,824$70M84
014BEAMBEAM THERAPEUTICS INC2.91%2,598,734$64M95
015WGSGENEDX HOLDINGS CORP2.53%531,493$56M72

Showing 1–15 of 33 holdings

ARKG Performance

Shows how $10,000 changes over the selected period, with cash distributions reinvested at the closing price on each ex-dividend date.

ARKG$18,984
SPY tracks large US stocks. It provides market context, rather than representing this fund’s strategy, asset class or investment benchmark.$11,723
Sep 22, 2025 to Sep 22, 2026. ARKG $18,984. SPY $11,723. Use the arrow keys to read each point.$8,106$13,948$19,790Sep 2025Mar 2026Sep 2026

Sep 22, 2025 – Sep 22, 2026

Returns run to the Sep 22, 2026 close, with cash distributions reinvested. Each period starts on the same date that many months or years earlier. Periods over one year show the average yearly return.

Trailing total return for ARKG. Periods over one year show the average yearly return.
PeriodARKG
Year to date+82.5%
1 month+6.9%
3 months+45.2%
1 year+89.8%
3 years+23.7%per year
5 years−8.0%per year
10 years+11.1%per year

As of the close, with distributions reinvested.

Calendar-year total return with cash distributions hypothetically reinvested at the ex-dividend date’s closing price. The current year shows year to date.

Annual total returns for ARKG
YearReturn barARKG
2026 YTD+82.5%
2025+23.0%
2024−28.2%
2023+16.2%
2022−53.9%
2021−33.9%
2020+180.6%

ARKG in the news

ARKG Dividends

Adds up every distribution paid per share over the last 12 months, divided by the last completed close. Distributions are counted by ex-date. Data through Sep 22, 2026.
0.00%Last 12 months
Payout per share
NoneLast 12 months

No distributions in the last 12 months.

Distribution history

Payments through 2021

One bar per payment. 5 payments from 2017 to 2021. Dec 27, 2017 $0.33; Dec 27, 2018 $0.47; Dec 27, 2019 $1.05; Dec 29, 2020 $0.79; Dec 29, 2021 $0.38. Use the arrow keys to read each point.20172018201920202021
Ex-datePay dateAmount per share
Dec 29, 2021Dec 31, 2021$0.38
Dec 29, 2020Dec 31, 2020$0.79
Dec 27, 2019Dec 31, 2019$1.05
Dec 27, 2018Dec 31, 2018$0.47
Dec 27, 2017Dec 29, 2017$0.33

ARKG Risk

How much the fund’s monthly returns vary, scaled to a year.
42.6%
Annualised · 36 months to Aug 2026
How it’s calculated: standard deviation

The sample standard deviation of monthly total returns, multiplied by the square root of 12.

Uses up to 36 complete months, with at least 12 required. Total returns include reinvested distributions.

Return above 3-month US Treasury bills per unit of volatility.
0.40
vs 3-month T-bills · to Aug 2026
How it’s calculated: Sharpe ratio

Subtract each month’s Treasury-bill return from the fund’s monthly total return.

Divide the average of those excess returns by their sample standard deviation, then multiply by the square root of 12.

Uses up to 36 complete months, with at least 12 required. Each month uses the Treasury yield quoted at the end of the previous month.

The largest fall from a peak to the low that followed.
−77.3%
Trough Apr 2025
How it’s calculated: maximum drawdown

The largest percentage decline from an earlier peak, using total returns with reinvested distributions.

Uses up to five years through the last close, with at least 12 months required.

How strongly the fund’s returns move with its asset-class index.
2.38
vs its asset-class index
How it’s calculated: beta

The beta figure is supplied by FMP. The comparison index depends on the fund’s broad asset class.

ARKG Cost

Expense ratio0.75%
  • The middle half of Biotech & Genomics funds
  • Median 0.47%

13 of the 15 Biotech & Genomics funds charge less.

ARKG costs $75.00 a year on $10,000. The median Biotech & Genomics fund costs $47.00.